AR and prostate cancer: No significant effect of TAS3681 was observed on the viability of AR‐negative cells, such as MIAPaCa‐2 (human pancreatic carcinoma), HCC1806 (human breast cancer), SK‐OV‐3 (human ovarian cancer), and DU145 (human prostate cancer) indicating that the antiproliferative effect of TAS3681 in AR‐positive PCa cells is mediated through AR antagonism (Figs S2 and S3).